Stemline Therapeutics, Inc.’s $88 Million Common Stock Offering

Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of approximately $88 million.

The common stock is listed on the Nasdaq Global Select Market under the symbol “STML.”

Stemline is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics.

J.P. Morgan, Cowen, Cantor, Ladenburg Thalmann, H.C. Wainwright & Co., ThinkEquity, A.G.P. and Aegis Capital Corp. acted as underwriters on the deal.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. (Picture) and Derek Dostal and associates Jacqueline Marino, Roman Shapurko and Concepción Olivera. Counsel Bonnie Chen and associate Yifu Chen provided intellectual property and technology advice. Partner William A. Curran provided tax advice.

Involved fees earner: Bonnie Chen – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; William Curran – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Jacqueline Marino – Davis Polk & Wardwell; Concepción Olivera – Davis Polk & Wardwell; Roman Shapurko – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: A.G.P. / Alliance Global Partners; Aegis Capital Corporation; Cantor Fitzgerald; Cowen and Company; H.C. Wainwright & Co.; J.P. Morgan Securities LLC; Ladenburg Thalmann Financial Services Inc.; ThinkEquity;


Author: Ambrogio Visconti